Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMQMV1B)

• Drug Name: Adalimumab Drug Info
• Synonyms: Humira; Adalimumab (genetical recombination); Humira (TN); Adalimumab (USAN/INN); Adalimumab (genetical recombination) (JAN)

Indication

Disease Entry	ICD 11	Status	REF
Crohn disease	DD70	Approved	[1]
Hidradenitis suppurativa	ED92.0	Approved	[2]
Mucositis	CA00	Approved	[3]
Psoriatic arthritis	FA21	Approved	[4]
Pyoderma gangrenosum	EB21	Approved	[5]
Rheumatoid arthritis	FA20	Approved	[6]
Sarcoidosis	4B20.5	Approved	[7]
Ulcerative colitis	DD71	Approved	[8]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Investigative	[9]

• Therapeutic Class: Antirheumatic Agents
• Cross-matching ID:
  TTD Drug ID: DMQMV1B
  VARIDT Drug ID: DR00441

Molecule-Related Drug Atlas

Drug(s) Targeting Tumor necrosis factor (TNF)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Thalidomide	DM70BU5	Adult T-cell leukemia/lymphoma		Approved	[11]
Nafamostat	DMU1XOD	Pancreatitis	DC31-DC34	Approved	[12]
Pentoxifylline	DMU3DNC	Alcoholic hepatitis	DB94.1	Approved	[13]
Lenalidomide	DM6Q7U4	Adult T-cell leukemia/lymphoma		Approved	[14]
Enbrel	DM7RNP3	Arthritis	FA20	Approved	[15]
Golimumab	DMHZV7X	Psoriatic arthritis	FA21	Approved	[16]
Certolizumab	DM5CL9Z	Rheumatoid arthritis	FA20	Approved	[17]
Etanercept	DMCV109	Arthritis	FA20	Approved	[18]
Infliximab	DMH7OIA	Crohn disease	DD70	Approved	[19]
Golnerminogene pradenovac	DMKWV4B	Esophageal cancer	2B70	Phase 3	[20]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Tumor necrosis factor (TNF)	TTF8CQI	TNFA_HUMAN	Not Available	[10]

References

• [1] Management of inflammatory bowel disease. Med J Aust. 2018 Sep 1;209(7):318-323.
• [2] Hidradenitis Suppurativa: Advances in Diagnosis and Treatment. JAMA. 2017 Nov 28;318(20):2019-2032.
• [3] Identification of potential molecular mechanisms and candidate drugs for radiotherapy- and chemotherapy-induced mucositis. Support Care Cancer. 2023 Mar 20;31(4):223.
• [4] Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis. N Engl J Med. 2021 Apr 1;384(13):1227-1239.
• [5] An update on adalimumab for pyoderma gangrenosum. Drugs Today (Barc). 2021 Sep;57(9):535-542.
• [6] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4860).
• [7] Sarcoidosis-associated acro-osteolysis. BMJ Case Rep. 2021 Mar 2;14(3):e240828.
• [8] First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis. Clin Gastroenterol Hepatol. 2020 Sep;18(10):2179-2191.e6.
• [9] Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed. Lancet. 2020 May 2;395(10234):1407-1409.
• [10] Adalimumab for psoriasis patients who are non-responders to etanercept: open-label prospective evaluation. J Eur Acad Dermatol Venereol. 2009 Dec;23(12):1394-7.
• [11] Efficacy of different thalidomide regimens for patients with multiple myeloma and its relationship with TNF-alpha level. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008 Dec;16(6):1312-5.
• [12] Clinical pipeline report, company report or official report of AstraZeneca (2009).
• [13] Targeted therapies in myelodysplastic syndromes: ASH 2003 review. Semin Hematol. 2004 Apr;41(2 Suppl 4):13-20.
• [14] Thalidomide and thalidomide analogues for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2009 Apr 15;(2):CD007351.
• [15] Oral pentoxifylline inhibits release of tumor necrosis factor-alpha from human peripheral blood monocytes : a potential treatment for aseptic loose... J Bone Joint Surg Am. 2001 Jul;83(7):1057-61.
• [16] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [17] Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96.
• [18] The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012 Dec;11(12):958-72.
• [19] Drug insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis. Nat Clin Pract Rheumatol. 2008 Jun;4(6):300-9.
• [20] TNFerade, an adenovector carrying the transgene for human tumor necrosis factor alpha, for patients with advanced solid tumors: surgical experience... Ann Surg Oncol. 2005 Oct;12(10):825-30.